GSK’s ViiV Sues Exavir Over Licensing Pact on HIV-Drug Compounds

GlaxoSmithKline PLC’s ViiV Healthcare Co. has sued Exavir Therapeutics Inc.’s alleging it licensing pact with the University of Nebraska on patents for compounds used in long-acting HIV therapies tortiously interferes with ViiV’s research collaboration agreement with the school and its business arm.

“Exavir’s use of the patents is divesting ViiV of its ownership rights, preventing ViiV from using its own intellectual property to compete in the flourishing biopharma industry and is causing irreparable harm to ViiV,” according to the GSK unit’s complaint filed Oct. 28 in Delaware’s Chancery Court.

The dispute is rooted in a research collaboration agreement between ...